A5049461398- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Chronic Myeloid Leukemia Treatments
- Biosimilars and Bioanalytical Methods
- Childhood Cancer Survivors' Quality of Life
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Cancer survivorship and care
- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Family Support in Illness
- Chemotherapy-induced cardiotoxicity and mitigation
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
Memorial Sloan Kettering Cancer Center
2016-2025
Rutgers, The State University of New Jersey
2023-2025
Rutgers Cancer Institute of New Jersey
2023-2024
Kettering University
2022-2024
Cornell University
2012-2023
Brunswick (United States)
2020-2023
New York Proton Center
2023
Dana-Farber Cancer Institute
2013-2023
Mayo Clinic
2023
WinnMed
2023
Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a receptor component.Safety and efficacy of bendamustine obinutuzumab (pola-BG) was evaluated in single-arm cohort. Polatuzumab combined rituximab (pola-BR) compared (BR) randomly assigned cohort patients R/R DLBCL (primary end point: independent review committee [IRC] assessed complete...
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage eliminate malignant B being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407) evaluated the safety tolerability efficacy of mosunetuzumab in patients with R/R B-NHL established recommended phase II dose. Data from dose escalation are presented. Single-agent was administered intravenously 3-week...
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) patients relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients Methods CD20+ DLBCL age ≥ 18 years who had experienced their first relapse were to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like treatment randomly assigned between...
We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov identifier: NCT03618550).Transplant eligible patients with rel/ref cHL following first-line were treated two to four cycles of (200 mg intravenous [IV], day 1), gemcitabine (1,000 mg/m2 IV, days 1 8), vinorelbine (20 (15 mg/m2, given on 21-day cycles. The...
Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines of treatment remains poorly described in the post-rituximab era. Also, Follicular Lymphoma International Prognostic Index (FLIPI) score was developed to predict at diagnosis, yet it unknown whether increase FLIPI following an initial observation period is associated less-favorable outcomes. To address these knowledge gaps, we retrospectively studied 1088...
Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of GO29365 study. After phase, 106 additional patients pola BR in a single-arm extension cohort. We report updated In this phase 1b/2 study, with R/R DLBCL who were transplant ineligible up to six 21-day cycles or BR. The end point was complete response (CR) rate at treatment. Primary...
As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines therapy). Intravenous was administered cycle (C) step-up dosing for cytokine release syndrome (CRS) mitigation: C1 day (D) 1: mg; C1D8 C1D15 C2D1: 60 C3 + D1: 30 mg. Hospitalization not mandatory. Patients complete response (CR) completed treatment after C8;...
JCO
Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated efficacy relapsed and refractory HL.Patients with HL who were ineligible for autologous stem-cell transplantation (ASCT), or whom this treatment failed, received 120 mg/m(2) as a 30-minute infusion on days 1 2 every 28 growth factor support. The primary end point was overall response rate (ORR). A secondary referral to allogeneic (alloSCT) patients deemed eligible alloSCT at time...
In randomized trials, patients with stage III colon cancer who received 6 months of fluorouracil (FU)-based adjuvant chemotherapy had better survival than did not. However, little is known about the predictors of, or associated with, duration in community.The linked Surveillance, Epidemiology, and End Results-Medicare database was used to identify individuals > = 65 years age diagnosed between 1995 1999. We logistic Cox proportional hazards regression models analyze factors early...
As the survival of patients with mantle cell lymphoma (MCL) continues to improve, are increasingly being treated multiple regimens. However, outcome after each line remains poorly characterized in modern era. To address this knowledge gap, we retrospectively studied 404 consecutive MCL who were managed between 2000 and 2014 at Memorial Sloan Kettering Cancer Center. Histologic diagnosis was centrally confirmed, followed longitudinally from throughout their disease course. Progression-free...
A cancer and fertility program was established at a large center to support clinicians in discussing treatment-related risks preservation (FP) options with patients referring reproductive specialists. The provides resources, clinician education, clinical nurse specialist consultation. This study evaluated the program's impact on patient satisfaction information received.Retrospective cross-sectional surveys assessed before (cohort 1 [C1]) after 2 [C2]) initiation. Questionnaires were...
The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R DLBCL after 2 prior lines based on data from single-arm phase trials, complete responses (CRs) in 40% to 60% patients. However, a direct comparison other treatments not available and, moreover, its true efficacy real-world unknown. In this single center, retrospective, observational study 215 patients, we compared...
Abstract CD20 is an established therapeutic target in B-cell malignancies. The × CD3 bispecific antibody mosunetuzumab has significant efficacy non-Hodgkin lymphomas (NHLs). Because antigen loss a recognized mechanism of resistance, we evaluated expression relative to clinical response patients with relapsed and/or refractory NHL the phase 1/2 GO29781 trial investigating monotherapy. was studied using immunohistochemistry (IHC), RNA sequencing, and whole-exome sequencing performed centrally...